logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics announces positive new clinic data with house-dust mite immunotherapy

The AIM-listed biotechnology company said the total of 141 patients were evaluated and they demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year

allergy
The company, specialising in allergy vaccines, said this observational study was conducted in ten sites across Spain

Allergy Therapeutics PLC (LON:AGY) said that house-dust immunotherapy has shown to be well-tolerated and demonstrates highly significant symptom improvement.

The AIM-listed biotechnology company said at the 37 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany, that this observational study was conducted in ten sites across Spain. The total 141 patients were evaluated and they demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year. 

READ: Allergy Therapeutics highlights benefits of adjuvant technology in new paper

In addition, in a subgroup of asthmatic subjects, 16.7% of patients were observed with moderate persistent asthma at one year compared with 50.9% at baseline.

The company, specialising in allergy vaccines, said its modified house-dust mite product sold as through a Named Patient Program in Spain, is the precursor to the modified house-dust mite + MPL product currently in Phase I.

Allergy Therapeutics said it presented a series of poster presentations at EAACI with key highlights and held a satellite symposium which provided a summary of how adjuvant technologies have evolved.

Manuel Llobet, chief executive officer, said in a statement: “The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength.”

He added: “And we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products."

Quick facts: Allergy Therapeutics PLC

Price: 11.7 GBX

AIM:AGY
Market: AIM
Market Cap: £74.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read